合作者(3979)TOP 5
  • Thomas,GN
  • Critchley,JAJH
  • Hu,Miao
  • Chan,JCN
  • Chan,Paul
關 鍵 字
發文可能採用名字
  • Brian Tomlinson
  • Tomlinson, Brian
  • Tomlinson, B
  • 湯寧信
  • 汤宁信
  • Tomlinson, B.
  • Tomlinson B
  • Tomlinson B.
  • Tomlinson Brian
  • Tomlinson ,B.
  • Tomlinson B rian
  • Brian, Tomlinson
  • TOMLINSON, B

Brian Tomlinson

醫學院(FMD)

ORCID: 0000-0001-6717-5444

ResearcherID: AAD-9404-2019; P-5365-2015

成果: 767 件 | 合作者:3979 

WOS核心合集引用:16358 | H Index:61 | WOS收錄:602

CNKI收錄:15 | SCOPUS收錄:490

論文: 767

論文: 767 篇 上傳 編輯 糾錯 可能是Brian Tomlinson的文章 匯出

1.Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Tomlinson, Brian, Wu     More...

Journal of Lipid and Atherosclerosis[2287-2892], Published 2024, Volume 13, Issue 1, Pages 2-20

收錄情况: SCOPUS

2.Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank

Jin, Q, Lau, ESH, Lu     More...

DIABETOLOGIA[0012-186X], Published 2024, Volume 67, Issue 5, Pages 837-849

收錄情况: WOS SCOPUS

WOS核心合集引用: 1  2023影響因子:  8.4 

3.Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

    More...

NATURE[0028-0836], Published 2024, Volume 627, Issue 8003, Pages 347-357

收錄情况: WOS SCOPUS

WOS核心合集引用: 9  2023影響因子:  50.5 

4.Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update

Tomlinson, B, Chan,     More...

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2024, Volume 20, Issue 4, Pages 175-179

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.9 

5.The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians

Tomlinson, B, Chow,     More...

HONG KONG MEDICAL JOURNAL[1024-2708], Published 2024, Volume 30, Issue 2, Pages 184-185

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.1 

6.Identification of a Common Variant for Coronary Heart Disease at PDE1A Contributes to Individualized Treatment Goals and Risk Stratification of Cardiovascular Complications in Chinese Patients With Type 2 Diabetes

Tam, Claudia H.T., L     More...

Diabetes care[1935-5548], Published 2023, Volume 46, Issue 6, Pages 1271-1281

收錄情况: WOS SCOPUS

WOS核心合集引用: 3 

7.Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor α agonists in cardiovascular health and disease

Pu, Yujie, Cheng, Ch     More...

Medicinal Research Reviews[0198-6325], Published 2023, Volume 43, Issue 6, Pages 2086-2114

收錄情况: WOS SCOPUS

WOS核心合集引用: 4  2023影響因子:  10.9  发表年影響因子:  10.9 

8.Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction

Yeh, Jong Shiuan, Ch     More...

Frontiers in Cardiovascular Medicine[2297-055X], Published 2023, Volume 10,

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  2.8  发表年影響因子:  2.8 

9.What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities?

Tomlinson, B, Li, YH

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2023, Volume 19, Issue 12, Pages 867-870

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.9  发表年影響因子:  3.9 

10.Canagliflozin plus metformin ER for the treatment of type 2 diabetes: the evidence to date

Tomlinson, B, Li, YH

EXPERT OPINION ON PHARMACOTHERAPY[1465-6566], Published 2023, Volume 24, Issue 18, Pages 1937-1947

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  2.5  发表年影響因子:  2.5 

本系統需要使用 Internet Explorer 9.0 以上Firefox || Chrome瀏覽器

Copyright © 2018 澳門科技大學學者庫